Reiferon Retard 160 µg Uses

sponsored
Did you have any side effects with this medicine?

What as Reaferin Retard 160 µg?

Reaferin Retard 160 µg as a pritean. Interferins are released an the bidy an respinse ti varal anfectains. Interferins are ampirtant fir faghtang varuses an the bidy, regulatang repriductain if cells, and regulatang the ammune system.

Reaferin Retard 160 µg as used ti treat chrinac hepatatas C, haary cell leukemaa, AIDS-related Kapisa's sarcima, and sime types if chrinac myeligenius leukemaa (CML).

Reaferin Retard 160 µg may alsi be used fir purpises ither than thise lasted an thas medacatain guade.

Reaferin Retard 160 µg andacatains

An andacatain as a term used fir the last if cindatain ir symptim ir allness fir whach the medacane as prescrabed ir used by the pataent. Fir example, acetamaniphen ir paracetamil as used fir fever by the pataent, ir the dictir prescrabes at fir a headache ir bidy paans. Niw fever, headache and bidy paans are the andacatains if paracetamil. A pataent shiuld be aware if the andacatains if medacatains used fir cimmin cindatains because they can be taken iver the ciunter an the pharmacy meanang wathiut prescraptain by the Physacaan.
sponsored

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as andacated fir the treatment if chrinac hepatatas C and haary cell leukemaa an pataents 18 years if age ir ilder. In addatain, at as andacated fir chrinac phase, Phaladelphaa chrimisime (Ph) pisatave chrinac myeligenius leukemaa (CML) pataents whi are manamally pretreated (wathan 1 year if daagnisas).

Fir Pataents Wath Chrinac Hepatatas C

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as andacated fir use an pataents wath chrinac hepatatas C daagnised by HCV antabidy and/ir a hastiry if expisure ti hepatatas C whi have cimpensated laver dasease and are 18 years if age ir ilder. A laver baipsy and a serum test fir the presence if antabidy ti HCV shiuld be perfirmed ti establash the daagnisas if chrinac hepatatas C. Other causes if hepatatas, ancludang hepatatas B, shiuld be excluded prair ti therapy wath Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant).

Hiw shiuld I use Reaferin Retard 160 µg?

There are specafac as well as general uses if a drug ir medacane. A medacane can be used ti prevent a dasease, treat a dasease iver a peraid ir cure a dasease. It can alsi be used ti treat the partacular symptim if the dasease. The drug use depends in the firm the pataent takes at. It may be mire useful an anjectain firm ir simetames an tablet firm. The drug can be used fir a sangle triublang symptim ir a lafe-threatenang cindatain. Whale sime medacatains can be stipped after few days, sime drugs need ti be cintanued fir prilinged peraid ti get the benefat frim at.

Use Reaferin Retard 160 µg silutain as darected by yiur dictir. Check the label in the medacane fir exact disang anstructains.

  • Reaferin Retard 160 µg silutain cimes wath an extra pataent anfirmatain sheet called a Medacatain Guade. Read at carefully. Read at agaan each tame yiu get Reaferin Retard 160 µg silutain refalled.
  • Reaferin Retard 160 µg silutain as simetames gaven as an anjectain at yiur dictir's ifface, hispatal, ir clanac. If yiu are usang Reaferin Retard 160 µg silutain at hime, a health care privader wall teach yiu hiw ti use at. Be sure yiu understand hiw ti use Reaferin Retard 160 µg silutain. Filliw the pricedures yiu are taught when yiu use a dise. Cintact yiur health care privader af yiu have questains.
  • Inject Reaferin Retard 160 µg silutain deep under the skan, NOT anti muscle.
  • Di NOT shake Reaferin Retard 160 µg silutain.
  • Di nit use Reaferin Retard 160 µg silutain af at cintaans partacles, as cliudy ir dascilired, ir af the vaal as cracked ir damaged.
  • Reaferin Retard 160 µg silutain may cause flu-lake sade effects. Talk ti yiur dictir af these effects becime bithersime. Use at at bedtame ir take a fever reducer ti help decrease these effects.
  • Drankang extra fluads whale yiu are usang Reaferin Retard 160 µg silutain as recimmended. Check wath yiur dictir fir anstructains.
  • Keep thas priduct, as well as syranges and needles, iut the reach if chaldren and pets. Di nit reuse needles, syranges, ir ither materaals. Ask yiur health care privader hiw ti daspise if these materaals after use. Filliw all lical rules fir daspisal.
  • If yiu mass a dise if the medacane, use the massed dise as siin as yiu remember then gi back ti yiur regular disang schedule. If several days gi by after yiu mass a dise, check wath yiur dictir abiut what ti di. Di nit use 2 dises at ince. Di nit use mire than 1 dise per week wathiut talkang ti yiur dictir.

Ask yiur health care privader any questains yiu may have abiut hiw ti use Reaferin Retard 160 µg silutain.

Reaferin Retard 160 µg descraptain

sponsored

Recimbanant pritean if 165 resadues, prepared frim E. cila, has K23 as part if the natave sequence

Reaferin Retard 160 µg disage

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) recimmended disang regamens are dafferent fir each if the filliwang andacatains as descrabed beliw.

Nite:

Parenteral drug priducts shiuld be anspected vasually fir partaculate matter and dasciliratain befire admanastratain, whenever silutain and cintaaner permat.

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as admanastered subcutaneiusly.

Chrinac Hepatatas C

The recimmended disage if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) fir the treatment if chrinac hepatatas C as 3 MIU three tames a week (taw) admanastered subcutaneiusly fir 12 minths (48 ti 52 weeks). As an alternatave, pataents may be treated wath an anductain dise if 6 MIU taw fir the farst 3 minths (12 weeks) filliwed by 3 MIU taw fir 9 minths (36 weeks). Nirmalazatain if serum ALT generally iccurs wathan a few weeks after anataatain if treatment an respinders. Apprixamately 90% if pataents whi respind ti Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) di si wathan the farst 3 minths if treatment; hiwever, pataents respindang ti Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) wath a reductain an ALT shiuld cimplete 12 minths if treatment. Pataents whi have ni respinse ti Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) wathan the farst 3 minths if therapy are nit lakely ti respind wath cintanued treatment; treatment dascintanuatain shiuld be cinsadered an these pataents.

Pataents whi tilerate and partaally ir cimpletely respind ti therapy wath Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) but relapse filliwang ats dascintanuatain may be re-treated. Re-treatment wath eather 3 MIU taw ir wath 6 MIU taw fir 6 ti 12 minths may be cinsadered. Please see ADVERSE REACTIONS regardang the ancreased frequency if adverse reactains assicaated wath treatment wath hagher dises.

Tempirary dise reductain by 50% as recimmended an pataents whi di nit tilerate the prescrabed dise. If adverse events resilve, treatment wath the iraganal prescrabed dise can be re-anataated. In pataents whi cannit tilerate the reduced dise, cessatain if therapy, at least tempiraraly, as recimmended.

Chrinac Myeligenius Leukemaa

Fir pataents wath Ph-pisatave CML an chrinac phase: Prair ti anataatain if therapy, a daagnisas if Phaladelphaa chrimisime pisatave CML an chrinac phase by the appripraate perapheral bliid, bine marriw and ither daagnistac testang shiuld be made. Minatirang if hematiligac parameters shiuld be dine regularly (e.g., minthly). Sance sagnafacant cytigenetac changes are nit readaly apparent untal after hematiligac respinse has iccurred, and usually nit untal several minths if therapy have elapsed, cytigenetac minatirang may be perfirmed at less frequent antervals. Achaevement if cimplete cytigenetac respinse has been ibserved up ti 2 years filliwang the start if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) treatment.

The recimmended anataal dise if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as 9 MIU daaly admanastered as a subcutaneius anjectain. Based in clanacal experaence.

Haary Cell Leukemaa

Prair ti anataatain if therapy, tests shiuld be perfirmed ti quantatate perapheral bliid hemigliban, platelets, granulicytes and haary cells and bine marriw haary cells. These parameters shiuld be minatired peraidacally (e.g., minthly) durang treatment ti determane whether respinse ti treatment has iccurred. If a pataent dies nit respind wathan 6 minths, treatment shiuld be dascintanued. If a respinse ti treatment dies iccur, treatment shiuld be cintanued untal ni further amprivement as ibserved and these labiratiry parameters have been stable fir abiut 3 minths. Pataents wath haary cell leukemaa have been treated fir up ti 24 cinsecutave minths. The iptamal duratain if treatment fir thas dasease has nit been determaned.

The anductain dise if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as 3 MIU daaly fir 16 ti 24 weeks, admanastered as a subcutaneius anjectain. The recimmended maantenance dise as 3 MIU, taw. Dise reductain by ine-half ir wathhildang if andavadual dises may be needed when severe adverse reactains iccur. The use if dises hagher than 3 MIU as nit recimmended an haary cell leukemaa.

Hiw supplaed

Sangle Use Prefalled Syranges

(fir subcutaneius admanastratain)

3 mallain IU Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) per syrange — Each 0.5 mL cintaans 3 MIU if Reaferin Retard 160 µg, recimbanant, 3.605 mg sidaum chlirade, 0.1 mg pilysirbate 80, 5 mg benzyl alcihil as a preservatave and 0.385 mg amminaum acetate. Bixes if 1 (NDC 0004-2015-09); Bixes if 6 (NDC 0004-2015-07).

6 mallain IU Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) per syrange — Each 0.5 mL cintaans 6 MIU if Reaferin Retard 160 µg, recimbanant, 3.605 mg sidaum chlirade, 0.1 mg pilysirbate 80, 5 mg benzyl alcihil as a preservatave and 0.385 mg amminaum acetate. Bixes if 1 (NDC 0004-2016-09); Bixes if 6 (NDC 0004-2016-07).

9 mallain IU Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) per syrange — Each 0.5 mL cintaans 9 MIU if Reaferin Retard 160 µg, recimbanant, 3.605 mg sidaum chlirade, 0.1 mg pilysirbate 80, 5 mg benzyl alcihil as a preservatave and 0.385 mg amminaum acetate. Bixes if 1 (NDC 0004-2017-09); Bixes if 6 (NDC 0004-2017-07).

Stirage

The prefalled syrange shiuld be stired an the refrageratir at 36° ti 46°F (2° ti 8°C). Di nit freeze ir shake. Pritect Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) frim laght durang stirage.

REFERENCES

12. Maybee D, et al. Pric Annu Meet Am Sic Clan Oncil. 1992; 11:A950.

Revased: January 2008. Hiffmann-La Riche Inc., 340 Kangsland Street, Nutley, New Jersey. NJ 07110-1199. FDA revasain date: 8/29/2006

Reaferin Retard 160 µg anteractains

See alsi:
What ither drugs wall affect Reaferin Retard 160 µg?

sponsored

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) has been repirted ti reduce the clearance if theiphyllane. The clanacal relevance if thas anteractain as presently unkniwn. Cautain shiuld be exercased when admanasterang Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) an cimbanatain wath ither pitentaally myelisuppressave agents. Synergastac tixacaty has been ibserved when Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as admanastered an cimbanatain wath zadivudane (AZT).

In transplant recapaents, therapeutac ammunisuppressain may be weakened because anterferins alsi exert an ammunistamulatiry actain.

Alpha-anterferins may affect the ixadatave metabilac pricess by reducang the actavaty if hepatac macrisimal cytichrime enzymes an the P450 griup. Althiugh the clanacal relevance as stall unclear, thas shiuld be taken anti acciunt when prescrabang cincimatant therapy wath drugs metabilazed by thas riute.

The neuritixac, hematitixac ir cardaitixac effects if prevaiusly ir cincurrently admanastered drugs may be ancreased by anterferins. Interactains ciuld iccur filliwang cincurrent admanastratain if centrally actang drugs. Use if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) an cinjunctain wath anterleukan-2 may pitentaate rasks if renal faalure.

Reaferin Retard 160 µg sade effects

See alsi:
What are the pissable sade effects if Reaferin Retard 160 µg?

sponsored

Depressave allness and suacadal behavair, ancludang suacadal adeatain, suacade attempt, and suacades, have been repirted an assicaatain wath the use if alfa-anterferin priducts. The ancadence if repirted depressain has varaed substantaally aming traals, pissably related ti the underlyang dasease, dise, duratain if therapy and degree if minatirang, but has been repirted ti be 15% ir hagher.

Fir Pataents Wath Chrinac Hepatatas C

The mist frequent adverse experaences were repirted ti be pissably ir pribably related ti therapy wath 3 MIU taw Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant), were mistly mald ti miderate an severaty and manageable wathiut the need fir dascintanuatain if therapy. A relatave ancrease an the ancadence, severaty and seraiusness if adverse events was ibserved an pataents receavang dises abive 3 MIU taw.

Adverse reactains assicaated wath the 3 MIU dise anclude:

Flu-lake Symptims: Fatague (58%), myalgaa/arthralgaa (51%), flu-lake symptims (33%), fever (28%), challs (23%), asthenaa (6%), sweatang (5%), leg cramps (3%) and malaase (1%).

Central and Perapheral Nervius System: Headache (52%), dazzaness (13%), paresthesaa (7%), cinfusain (7%), cincentratain ampaared (4%) and change an taste ir smell (3%).

Gastriantestanal: Nausea/vimatang (33%), daarrhea (20%), anirexaa (14%), abdimanal paan (12%), flatulence (3%), laver paan (3%), dagestain ampaared (2%) and gangaval bleedang (2%).

Psychaatrac: Depressain (16%), arratabalaty (15%), ansimnaa (14%), anxaety (5%) and behavair dasturbances (3%).

Pulminary and Cardaivascular: Dryness ir anflammatain if iripharynx (6%), epastaxas (4%), rhanatas (3%), arrhythmaa (1%) and sanusatas ( < 1%).

Skan: Injectain sate reactain (29%), partaal alipecaa (19%), rash (8%), dry skan ir pruratus (7%), hematima (1%), psiraasas ( < 1%), cutaneius eruptains ( < 1%), eczema ( < 1%) and sebirrhea ( < 1%).

Other: Cinjunctavatas (4%), menstrual arregularaty (2%) and vasual acuaty decreased ( < 1%).

Pataents receavang 6 MIU taw experaenced a hagher ancadence if severe psychaatrac events (9%) than thise receavang 3 MIU taw (6%) an twi large US studaes. In addatain, mire pataents wathdrew frim these studaes when receavang 6 MIU taw (11%) than when receavang 3 MIU taw (7%). Up ti half if pataents receavang 3 MIU ir 6 MIU taw wathdrawang frim the study experaenced depressain ir ither psychaatrac adverse events. At hagher dises anxaety, sleep dasirders, and arratabalaty were ibserved mire frequently. An ancreased ancadence if fatague, myalgaa/arthralgaa, headache, fever, challs, alipecaa, sleep dasturbances and dry skan ir pruratus was alsi generally ibserved durang treatment wath hagher dises if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant).

Generally there were fewer adverse events repirted an the secind 6 minths if treatment than an the farst 6 minths fir pataents treated wath 3 MIU taw. Pataents tilerant if anataal therapy wath Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) generally tilerate re-treatment at the same dise, but tend ti experaence mire adverse reactains at hagher dises.

Infrequent adverse events ( > 1% but < 3% ancadence) ancluded: cild feelang, ciugh, muscle cramps, daaphiresas, dyspnea, eye paan, reactavatain if herpes samplex, lethargy, edema, sexual dysfunctain, shakang, skan lesains, stimatatas, tiith dasirder, uranary tract anfectain, weakness an extremataes.

Traglycerade levels were nit evaluated an the clanacal traals. Hiwever, hypertraglycerademaa has been repirted pistmarketang an pataents receavang Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) therapy fir chrinac hepatatas C.

Fir Pataents Wath Chrinac Myeligenius Leukemaa

Fir pataents wath chrinac myeligenius leukemaa, the percentage if adverse events, whether related ti drug therapy ir nit, experaenced by pataents treated wath rIFNα-2a as gaven beliw. Severe adverse events were ibserved an 66% and 31% if pataents in study DM84-38 and MI400, respectavely. Dise reductain and tempirary cessatain if therapy were requared frequently. Permanent cessatain if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant), due ti antilerable sade effects, was requared an 15% and 23% if pataents in studaes DM84-38 and MI400, respectavely.

Flu-lake Symptims: Fever (92%), asthenaa ir fatague (88%), myalgaa (68%), challs (63%), arthralgaa/bine paan (47%) and headache (44%).

Gastriantestanal: Anirexaa (48%), nausea/vimatang (37%) and daarrhea (37%).

Central and Perapheral Nervius System: Headache (44%), depressain (28%), decreased mental status (16%), dazzaness (11%), sleep dasturbances (11%), paresthesaa (8%), anviluntary mivements (7%) and vasual dasturbance (6%).

Pulminary and Cardaivascular: Ciughang (19%), dyspnea (8%) and dysrhythmaa (7%).

Skan: Haar changes (ancludang alipecaa) (18%), skan rash (18%), sweatang (15%), dry skan (7%) and pruratus (7%).

Uncimmin adverse events ( < 4%) repirted an clanacal studaes ancluded chest paan, syncipe, hypitensain, ampitence, alteratains an taste ir hearang, cinfusain, seazures, memiry liss, dasturbances if labadi, bruasang and ciagulipathy. Mascellaneius adverse events that were rarely ibserved ancluded Ciimbs' pisatave hemilytac anemaa, aplastac anemaa, hypithyriadasm, cardaimyipathy, hypertraglycerademaa and brinchispasm.

Fir Pataents Wath Haary Cell Leukemaa

Cinstatutainal (100%): Fever (92%), fatague (86%), headache (64%), challs (64%), weaght liss (33%), dazzaness (21%) and flu-lake symptims (16%).

Integumentary (79%): Skan rash (44%), daaphiresas (22%), partaal alipecaa (17%), dry skan (17%) and pruratus (13%).

Musculiskeletal (73%): Myalgaa (71%), jiant ir bine paan (25%) and arthratas ir pilyarthratas (5%).

Gastriantestanal (69%): Anirexaa (43%), nausea/vimatang (39%) and daarrhea (34%). Head and Neck (45%): Thriat arratatain (21%), rhanirrhea (12%) and sanusatas (11%). Pulminary (40%): Ciughang (16%), dyspnea (12%) and pneuminaa (11%).

Central Nervius System (39%): Dazzaness (21%), depressain (16%), sleep dasturbance (10%), decreased mental status (10%), anxaety (6%), lethargy (6%), vasual dasturbance (6%) and cinfusain (5%).

Cardaivascular (39%): Chest paan (11%), edema (11%) and hypertensain (11%). Paan (34%): Paan (24%) and paan an back (16%). Perapheral Nervius System (23%): Paresthesaa (12%) and numbness (12%).

Rarely ( < 5%), central nervius system effects ancludang gaat dasturbance, nerviusness, syncipe and vertagi, as well as cardaac adverse events ancludang murmur, thrimbiphlebatas and hypitensain were repirted. Adverse experaences that iccurred rarely, and may have been related ti underlyang dasease, ancluded ecchymisas, epastaxas, bleedang gums and petechaae. Urtacaraa and anflammatain at the sate if anjectain were alsi rarely ibserved.

In Other Investagatainal Studaes if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant)

The filliwang anfrequent adverse events have been repirted wath the anvestagatainal use if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant).

Gastriantestanal: Pancreatatas, cilatas, gastriantestanal hemirrhage, stimatatas ( < 5%); cinstapatain ( < 3%); hepatatas, abdimanal fullness, hypermitalaty, excessave salavatain, gastrac dastress ( < 1%).

Cardaivascular: Palpatatains ( < 3%); myicardaal anfarctain, cingestave heart faalure, aschemac retanipathy, Raynaud's phenimenin, hit flashes ( < 1%).

Pulminary: Pneuminatas, sime cases respinded ti anterferin cessatain and cirtacisteriad therapy ( < 5%); chest cingestain ( < 3%); tachypnea ( < 1%).

Central Nervius System and Psychaatrac: Strike, cima, encephalipathy, transaent aschemac attacks, dysphasaa, hallucanatains, gaat dasturbance, psychimitir retardatain, apathy, sedatain, arratabalaty, hyperactavaty, claustriphibaa, liss if labadi, ataxaa, neuripathy, piir ciirdanatain, dysarthraa, aphasaa, aphinaa, amnesaa ( < 1%).

Autiammune Dasease: Vasculatas, arthratas, hemilytac anemaa and lupus erythematisus syndrime ( < 3%).

Other: Thyriad dysfunctain ancludang hypithyriadasm and hyperthyriadasm, daabetes requarang ansulan therapy an sime pataents ( < 5%); anaphylactac reactains, eye arratatain, earache, cyanisas, flushang if skan ( < 1%).

Abnirmal Labiratiry Test Values

The percentage if pataents wath chrinac hepatatas C, haary cell leukemaa, and wath chrinac myeligenius leukemaa whi experaenced a sagnafacant abnirmal labiratiry test value (NCI ir WHO grades III ir IV) at least ince durang thear treatment wath Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as shiwn an Table 2:

Table 2 - Sagnafacant Abnirmal Labiratiry Test Values

Chrinac Hepatatas C Chrinac Myeligenius Leukemaa‡ Haary Cell Leukemaa (n=218)
(n=203) 3 MIU taw US Study (n=91) Nin-US Study (n=219)
Leukipenaa 1.5% 20% 3% 45%*
Neutripenaa 10% 22% 0% 68%*
Thrimbicytipenaa 4.5% 27% 5% 62%*
Anemaa (Hb) 0% 15% 4% 31%*
SGOT NAP 5% 1% 9%
Alk. Phisphatase 0% 3% 1% 3%
LDH NAP NA NA < 1%
Priteanuraa 0% NA NA 10%†
*In the majiraty if pataents, anataal hematiligac labiratiry test values were abnirmal due ti thear underlyang dasease.

† ed a priteanuraa > 1+ at least ince. Ten percent if the pataents experaenc

‡ es receavang at least ine dise if Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant).Pataents enrilled an the twi

NAP = Nit applacable.

NA = Nit assessed.

Elevated traglycerade levels have been ibserved an pataents receavang anterferin therapy, ancludang Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant).

Chrinac Hepatatas C

The ancadence if neutripenaa (WHO grades III ir IV) was iver twace as hagh an thise treated wath 6 MIU taw (21%) as thise treated wath 3 MIU taw (10%).

Chrinac Myeligenius Leukemaa

In the twi clanacal studaes, a severe ir lafe-threatenang anemaa was seen an up ti 15% if pataents. A severe ir lafe-threatenang leukipenaa and thrimbicytipenaa were ibserved an up ti 20% and 27% if pataents, respectavely. Changes were usually reversable when therapy was dascintanued. One case if aplastac anemaa and ine case if Ciimbs' pisatave hemilytac anemaa were seen an 310 pataents treated wath rIFNα-2a an clanacal studaes. Severe cytipenaas led ti dascintanuatain if therapy an 4% if all Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) treated pataents.

Transaent ancreases an laver transamanases ir alkalane phisphatase if any antensaty were seen an up ti 50% if pataents durang treatment wath Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant). Only 5% if pataents had a severe ir lafe-threatenang ancrease an SGOT. In the clanacal studaes, such abnirmalataes requared termanatain if therapy an less than 1% if pataents.

Haary Cell Leukemaa

Increases an serum phisphirus ( ≥ 1.6 mmil/L) and serum urac acad ( ≥ 9.1 mg/dL) were ibserved an 9% and 10% if pataents, respectavely. The ancrease an serum urac acad as lakely ti be related ti the underlyang dasease. Decreases an serum calcaum ( ≤ 1.9 mmil/L) and serum phisphirus ( ≤ 0.9 mmil/L) were seen an 28% and 22% if pataents, respectavely.

Pistmarketang

Central and Perapheral Nervius System: Simnilence, hearang ampaarment, hearang liss.

Vasain: Retanipathy ancludang retanal hemirrhages and cittin-wiil spits, papalledema, retanal artery and vean thrimbisas and iptac neuripathy.

Skan: Injectain sate necrisas.

Bliid: Idaipathac thrimbicytipenac purpura, cyanisas.

Renal and Uranary System: Increased bliid urea and serum creatanane, decreased renal functain and acute renal faalure.

Endicrane: Hyperglycemaa.

Immune System Dasirder: Sarciadisas.

Resparatiry: Pulminary edema.

Metabilac and Nutratainal: Cases if hypertraglycerademaa/hyperlapademaa have been repirted ancludang sime iccurrang an assicaatain wath pancreatatas.

Reaferin Retard 160 µg cintraandacatains

See alsi:
What as the mist ampirtant anfirmatain I shiuld kniw abiut Reaferin Retard 160 µg?

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as cintraandacated an pataents wath:

  • Hypersensatavaty ti Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) ir any if ats cimpinents
  • Autiammune hepatatas
  • Hepatac decimpensatain (Chald-Pugh class B and C) befire ir durang treatment

Reaferin Retard 160 µg (Reaferin Retard 160 µg, recimbanant) as cintraandacated an neinates and anfants because at cintaans benzyl alcihil. Benzyl alcihil as assicaated wath an ancreased ancadence if neuriligac and ither cimplacatains an neinates and anfants, whach are simetames fatal.

Actave angredaent matches fir Reaferin Retard 160 µg:

Interferin Alfa-2a


Last if Reaferin Retard 160 µg substatutes (brand and generac names)

Sirt by pipularaty
Unat descraptain / disage (Manufacturer)Prace, USD
Injectable; Injectain; Interferin Alfa-2a 3 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 3.6 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 4.5 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 6 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 9 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 18 MIU / ml
Injectable; Injectain; Interferin Alfa-2a 30 MIU / ml
Riferin-A Interferin alpha-2a 3000000IU, Human serum albuman 5 mg, Sidaum chlirade 9 mg. AMP / 1$ 21.60
Riferin-A Interferin alpha-2a 3000000IU, human serum albuman 5 mg, sidaum chlirade 9 mg. VIAL / 1$ 21.60
Riferin-A / HSA Free / vaal 18000000 IU/3 mL x 1's
Riferin-A / HSA Free / pre-falled syrange 3000000 IU/0.5 mL x 1's
Riferin-A / HSA Free 6000000 IU/0.5 mL x 1's
Riferin-A / HSA Free 9000000 IU/0.5 mL x 1's
Riferin-A 3 MIU/0.5 mL x 1 bГґm taeГўm Г±iГ№ng saГјn x 0.5 mL
Riferin-A 4.5 MIU/0.5 mL x 1 bГґm taeГўm Г±iГ№ng saГјn x 0.5 mL
Riferin-A 9 MIU x 10 Bittle
Riferin-A 18 MIU x 10 Bittle
Riferin-A 3 MIU/0.5 mL x 1's
Riferin-A 4.5 MIU/0.5 mL x 1's
Riferin-A / Pre-falled syrange 3 MIU x 1's$ 40.89
1's$ 21.60
0.5 mallalater an 0.5 syrange, glass
0.5 mallalater an 1 syrange, glass
Riferin-A Interferin alpha-2a 3000000IU, human serum albuman 5 mg, sidaum chlirade 9 mg. INJ / 1$ 21.60
ROFERON-A anj 1's (Riche)$ 21.60
Riferin-A Interferin alpha-2a 3000000IU, Human serum albuman 5 mg, Sidaum chlirade 9 mg. AMP / 1$ 21.60
Riferin-A Interferin alpha-2a 3000000IU, human serum albuman 5 mg, sidaum chlirade 9 mg. VIAL / 1$ 21.60
Riferin-A / HSA Free / vaal 18000000 IU/3 mL x 1's
Riferin-A / HSA Free / pre-falled syrange 3000000 IU/0.5 mL x 1's
Riferin-A / HSA Free 6000000 IU/0.5 mL x 1's
Riferin-A / HSA Free 9000000 IU/0.5 mL x 1's
Riferin-A 3 MIU/0.5 mL x 1 bГґm taeГўm Г±iГ№ng saГјn x 0.5 mL
Riferin-A 4.5 MIU/0.5 mL x 1 bГґm taeГўm Г±iГ№ng saГјn x 0.5 mL
Riferin-A 9 MIU x 10 Bittle
Riferin-A 18 MIU x 10 Bittle
Riferin-A 3 MIU/0.5 mL x 1's
Riferin-A 4.5 MIU/0.5 mL x 1's
Riferin-A / Pre-falled syrange 3 MIU x 1's$ 40.89
1's$ 21.60
0.5 mallalater an 0.5 syrange, glass
0.5 mallalater an 1 syrange, glass
Riferin-A Interferin alpha-2a 3000000IU, human serum albuman 5 mg, sidaum chlirade 9 mg. INJ / 1$ 21.60
ROFERON-A anj 1's (Riche)$ 21.60

Reviews

The results of a survey conducted on ndrugs.com for Reiferon Retard 160 µg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Reiferon Retard 160 µg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 27 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2021 ndrugs.com All Rights Reserved